These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 18483661

  • 21. The success of bariatric surgery as treatment of type 2 diabetes should be a call to revitalize anti-obesity drug discovery and development.
    Opgenorth TJ.
    Curr Opin Investig Drugs; 2008 Apr; 9(4):355-6. PubMed ID: 18393101
    [No Abstract] [Full Text] [Related]

  • 22. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E, Minuto F, Colao A, Ferone D.
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [Abstract] [Full Text] [Related]

  • 23. The adipocyte IKK/NFkappaB pathway: a therapeutic target for insulin resistance.
    Ruan H, Pownall HJ.
    Curr Opin Investig Drugs; 2009 Apr; 10(4):346-52. PubMed ID: 19337955
    [Abstract] [Full Text] [Related]

  • 24. [Type 2 diabetes and impaired glucose tolerance].
    Furukawa N, Araki E.
    Nihon Rinsho; 2013 Feb; 71(2):270-4. PubMed ID: 23631205
    [Abstract] [Full Text] [Related]

  • 25. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.
    Arakawa M, Ebato C, Mita T, Fujitani Y, Shimizu T, Watada H, Kawamori R, Hirose T.
    Metabolism; 2008 Sep; 57(9):1299-306. PubMed ID: 18702958
    [Abstract] [Full Text] [Related]

  • 26. [Metformin role in the treatment of type 2 diabetes in 2008].
    Spada A, Philippe J.
    Rev Med Suisse; 2008 Jun 04; 4(160):1392-4, 1396-7. PubMed ID: 18630062
    [Abstract] [Full Text] [Related]

  • 27. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
    Campbell RK.
    J Am Pharm Assoc (2003); 2009 Jun 04; 49 Suppl 1():S10-5. PubMed ID: 19801360
    [Abstract] [Full Text] [Related]

  • 28. GPR43: an emerging target for the potential treatment of type 2 diabetes, obesity and insulin resistance.
    Tiwari A.
    Curr Opin Investig Drugs; 2010 Apr 04; 11(4):385-93. PubMed ID: 20336586
    [Abstract] [Full Text] [Related]

  • 29. Recent advances in glucokinase activators for the treatment of type 2 diabetes.
    Pal M.
    Drug Discov Today; 2009 Aug 04; 14(15-16):784-92. PubMed ID: 19520181
    [Abstract] [Full Text] [Related]

  • 30. Overcoming insulin resistance with ciliary neurotrophic factor.
    Allen TL, Matthews VB, Febbraio MA.
    Handb Exp Pharmacol; 2011 Aug 04; (203):179-99. PubMed ID: 21484573
    [Abstract] [Full Text] [Related]

  • 31. FGF21: a novel prospect for the treatment of metabolic diseases.
    Kharitonenkov A, Shanafelt AB.
    Curr Opin Investig Drugs; 2009 Apr 04; 10(4):359-64. PubMed ID: 19337957
    [Abstract] [Full Text] [Related]

  • 32. Regulation of glucose-6-phosphatase gene expression by insulin and metformin.
    Mues C, Zhou J, Manolopoulos KN, Korsten P, Schmoll D, Klotz LO, Bornstein SR, Klein HH, Barthel A.
    Horm Metab Res; 2009 Oct 04; 41(10):730-5. PubMed ID: 19579180
    [Abstract] [Full Text] [Related]

  • 33. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes.
    Scheen AJ, Van Gaal LF.
    Lancet Diabetes Endocrinol; 2014 Nov 04; 2(11):911-22. PubMed ID: 24731666
    [Abstract] [Full Text] [Related]

  • 34. Thermogenic and metabolic antiobesity drugs: rationale and opportunities.
    Clapham JC, Arch JR.
    Diabetes Obes Metab; 2007 May 04; 9(3):259-75. PubMed ID: 17391151
    [Abstract] [Full Text] [Related]

  • 35. Pharmacologic modifications of hormones to improve their therapeutic potential for diabetes management.
    Garber AJ.
    Diabetes Obes Metab; 2005 Nov 04; 7(6):666-74. PubMed ID: 16219010
    [Abstract] [Full Text] [Related]

  • 36. Leapin' lizards: Amylin targets diabetes and obesity via incretins.
    Wolfson W.
    Chem Biol; 2007 Mar 04; 14(3):235-6. PubMed ID: 17379135
    [No Abstract] [Full Text] [Related]

  • 37. New hepatic targets for glycaemic control in diabetes.
    Agius L.
    Best Pract Res Clin Endocrinol Metab; 2007 Dec 04; 21(4):587-605. PubMed ID: 18054737
    [Abstract] [Full Text] [Related]

  • 38. Improvement of diabetes, obesity and hypertension in type 2 diabetic KKAy mice by bis(allixinato)oxovanadium(IV) complex.
    Adachi Y, Yoshikawa Y, Yoshida J, Kodera Y, Katoh A, Takada J, Sakurai H.
    Biochem Biophys Res Commun; 2006 Jul 07; 345(3):945-50. PubMed ID: 16707105
    [Abstract] [Full Text] [Related]

  • 39. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S.
    Diabetes Metab; 2008 Feb 07; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [Abstract] [Full Text] [Related]

  • 40. Arylalkylamine vanadium salts as new anti-diabetic compounds.
    Zorzano A, Palacín M, Marti L, García-Vicente S.
    J Inorg Biochem; 2009 Apr 07; 103(4):559-66. PubMed ID: 19246098
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.